Oculis to unveil June topline Phase 3 DIAMOND results and ACUITY post-hoc OCT data
OCS•Oculis will present DME AWARE Delphi Study findings showing consensus on diabetic macular edema needs and post-hoc OCT data demonstrating Privosegtor’s reduction in retinal ganglion cell loss with 15-30 letter gains. The company completed its Phase 3 DIAMOND patient visits and expects topline OCS-01 eye drop results in June 2026.
1. Presentations at ARVO and Eyecelerator
Oculis will showcase its late-stage pipeline at the Eyecelerator session on May 1 and at the ARVO Annual Meeting from May 4–6. CEO Riad Sherif will lead a company update on regulatory milestones for Privosegtor and the completion of the DIAMOND Phase 3 patient visits, while experts will present on DME management and neuroprotective trial data.
2. DME AWARE Delphi Study Findings
The DME AWARE Delphi Study, involving a global panel of 25 retina experts, reached consensus on significant gaps in diabetic macular edema management and the need for non-invasive therapies. Interim surveys highlighted Best Corrected Visual Acuity loss considerations, early intervention criteria and definitions of ‘poor’ and ‘non-response’ to existing treatments.
3. ACUITY Trial Post-hoc Analysis
Post-hoc OCT analysis from the Phase 2 ACUITY trial showed that Privosegtor treatment reduced retinal ganglion cell loss and delivered 15- and 30-letter gains in low-contrast visual acuity. Privosegtor has Breakthrough Therapy designation in optic neuritis and PRIME status in the EU, with the PIONEER-1 registrational trial initiated in Q4 2025.
4. Phase 3 DIAMOND Program and Pipeline Updates
Oculis completed the last patient visit in its DIAMOND Phase 3 program for OCS-01 eye drops in April and expects topline results in June 2026. The company is also advancing Licaminlimab through its PREDICT registrational program and preparing for key upcoming clinical and regulatory milestones.
